Nova Biomedical Integrates PAIA Titer Technology
The integration aims to accelerate cell line development by combining imaging with productivity data.
Updated on Oct. 22, 2026 in Biotech
Live Poll
Does integrating automated data tools into research workflows improve scientific decision-making in your area?
Nova Biomedical has integrated PAIA Titer assay technology into its VIPS PRO and Cell Metric X platforms. This update allows scientists to access productivity and product quality data earlier in the cell line development workflow.
Why it matters
Researchers require early data to prioritize promising clones effectively. This integration prevents the investment of time and resources into expanding candidate clones that lack future potential.
The VIPS PRO platform utilizes nanodroplet single-cell seeding alongside AI-assisted detection. Meanwhile, the Cell Metric X provides high-resolution, multi-plane whole-well imaging that supports both standalone and robotic environments.
The players
Nova Biomedical
Nova Biomedical is a life sciences company that specializes in technology for cell line development and bioprocessing.
The details
By combining image-based clonality evidence with productivity data, the platforms offer a double-lock assurance during the initial phases of cloning. Scientists can now evaluate performance metrics alongside imaging data starting on day 0 of the development process.
Timeline
Day 0: The VIPS PRO platform provides image-based clonality evidence.
The Tech Race
This integration marks an evolution of the VIPS PRO and Cell Metric X platform workflows toward more integrated, high-throughput bioprocessing systems. By automating the combination of imaging and quality data, Nova Biomedical positions its hardware to compete in the increasingly rapid field of pharmaceutical cell development.
Biotech researchers can now streamline their daily workflows by obtaining quality metrics simultaneously with clonality evidence. This reduction in manual steps minimizes the time spent processing non-viable samples in the lab.
The takeaway
The addition of assay technology directly into imaging hardware signals a shift toward more comprehensive automated laboratory analysis. Researchers should evaluate whether these dual-purpose platforms can reduce their internal clone screening timelines.
Further reading
Learn more about the latest innovations in the field at Biotech.
Source note: This article includes information reported by Selectscience.
Live Poll
Does integrating automated data tools into research workflows improve scientific decision-making in your area?
